Scientific Merits of Verve Therapeutics' (VERV) PCSK9 Exist, but Worries on Commercial Appeal Remain - Stifel
Tweet Send to a Friend
Stifel analyst Dae Gon Ha reiterated a Hold rating on Verve Therapeutics (NASDAQ: VERV), following a recent business update by ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
